PapersPMID:41565787
Evaluating the antioxidant and anti-inflammatory effect of melatonin in pediatric hemodialysis patients: a randomized, placebo-controlled trial.
No finding here moved its endpoint.
What did not
1 findingHow to read these marks →“Also, the MLT group demonstrated marginal reduction in MDA compared to placebo group (F = 3.046, p = 0.092, partial η2 = 0.095), revealing a trend towards decreased oxidative stress that did not reach statistical significance.”
- Study
- RCT
- Duration
- 3 months
- Dose studied
- 5 mg oral melatonin once daily 1 h before bedtime for 12 weeks
- Population
- children on chronic haemodialysis; primary endpoint, ANCOVA adjusted for baseline MDA and antihypertensive use; serum MDA by ELISA
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- 40 pediatric hemodialysis patients aged 6-18 years
- Participants
- 40
- Comparator
- placebo
- Duration
- 84 days
- Endpoints measured
- 6
melatonin